Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 2
---
22 of the Registration Statement, NLS undertook to file this Post -EffectiveAmendment No. 1 to include any financial statements required by Item 8.A of Form 20 -Fat the start of any delayed offering or throughout a continuous offering. Pursuant to Item 512(a)(4) of Regulation S -K, financial statements and information otherwise required by Section 10(a)(3) of the Securities Act of 1933, as amended, or the Securities Act, are not required to be furnished herewith, provided that NLS includes in the proxy statement/prospectus, or the Prospectus, included in the Registration Statement, by means hereof, financial statements required by Item 8.A of Form 20 -Fand other information as aforesaid. NLS filed the final Prospectus dated as of September 9, 2025 pursuant to Rule 424(b)(3) under the Securities Act, or the Prospectus. This Post -EffectiveAmendment No. 1 includes a supplement, or the Supplement, to the Prospectus containing the financial statements and other information required by Item 512(a)(4) of Regulation S -K. The Supplement updates the information contained in the Prospectus and should be read together therewith.

The information in this Supplement to Proxy Statement/Prospectus is not complete and may be changed. This Supplement to Proxy Statement/Prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to Completion
Supplement Dated October 17, 2025 to
Proxy Statement/Prospectus Dated September 9, 2025

| SUPPLEMENT TO              |
| PROXY STATEMENT/PROSPECTUS |

NLS PHARMACEUTICS LTD. NLS Pharmaceutics Ltd., or NLS, previously registered with the U.S. Securities and Exchange Commission, or the SEC, 70,000,000 common shares, 0.03 Swiss Franc (CHF) par value per share, or the NLS Common Shares, and up to 70,000,000 pre-funded warrants to purchase 70,000,000 NLS Common Shares. NLS previously filed with the U.S. Securities and Exchange Commission, or the SEC, a Proxy Statement/Prospectus dated as of September 9, 2025, or the Prospectus, relating to the NLS Common Shares and pre-funded warrants